CPC technology class · C07
C07B — General Methods OF Organic Chemistry
General methods of organic chemistry; apparatus therefor. 8,058 US utility patents granted 2015–2025, with the leading assignees and year-by-year filing trajectory.
- 8,058
- US patents granted
- C07
- Parent CPC class
- 20
- Active assignees
- +36%
- 5-yr velocity
CPC subclass C07B — GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR — covers 8,058 US utility patents granted between 2015 and 2025 according to USPTO PatentsView records. This subclass sits within the broader CPC class C07 (ORGANIC CHEMISTRY), one of roughly 250 top-level technology categories in the Cooperative Patent Classification system jointly maintained by the USPTO and the European Patent Office. At the subclass level, four-character codes like C07B give the most practical resolution for tracking a specific technology domain without losing sight of adjacent filings. Every grant here has been classified by a USPTO examiner based on the technical disclosure in the patent specification.
The competitive landscape in C07B is shaped by 20 distinct companies actively filing in this space. Incyte Corporation leads with 89 patents, followed by Novartis AG at 1,768 grants and Bristol-Myers Squibb Company at 1,089. Concentration at the top of the leaderboard indicates whether this technology area is dominated by a handful of incumbents or fragmented across many filers — a useful signal for investors evaluating competitive moats and for product teams mapping freedom-to-operate risk.
Filing trajectory matters as much as static counts. The yearly series on this page plots grants from 2015 through 2025, highlighting whether innovation in C07B is accelerating, plateauing, or cooling. Technology areas with rising post-2020 activity often reflect emerging markets or new platform shifts, while declining filings can signal mature domains where incremental improvement has slowed. Researchers, licensing professionals, and competitive-intelligence teams use these patterns — together with the top-assignee distribution — to decide where to invest, where to license, and where to avoid entanglement. All counts on this page come directly from USPTO PatentsView and reflect US granted utility patents only.
Is C07B innovation accelerating?
US utility-patent grants per year in C07B, 2015–2025 — recent five years are up 36% versus 2015–2019.
Who leads C07B?
The 12 most active assignees in GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR — wider bars mean more grants
- Incyte 652
Incyte Corporation
652 patents
- Novartis
Novartis AG
1,768 patents
- Bristol-myers Squibb
Bristol-Myers Squibb Company
1,089 patents
- Abb Vie 604
Abb Vie Inc.
604 patents
- Pfizer 659
PFIZER INC.
659 patents
- Concert Pharmaceutica… 73
Concert Pharmaceuticals, Inc.
73 patents
- Gilead Sciences 561
Gilead Sciences, Inc.
561 patents
- Vertex Pharmaceutical… 334
Vertex Pharmaceuticals Incorporated
334 patents
- Merck Sharp & Dohme
Merck Sharp & Dohme LLC
1,248 patents
- Janssen Pharmaceutica…
Janssen Pharmaceuticals, Inc.
769 patents
- Celgene 313
CELGENE CORPORATION
313 patents
- Theravance Biopharma… 239
Theravance Biopharma R&D IP, LLC
239 patents
What this shows Incyte is the most active filer in C07B, holding 89 of the 8,058 patents in this class. Concentration at the top signals how contestable this technology area is for new entrants.
View data table
| Rank | Company | Patents in C07B |
|---|---|---|
| #1 | Incyte Corporation | 652 |
| #2 | Novartis AG | 1,768 |
| #3 | Bristol-Myers Squibb Company | 1,089 |
| #4 | Abb Vie Inc. | 604 |
| #5 | PFIZER INC. | 659 |
| #6 | Concert Pharmaceuticals, Inc. | 73 |
| #7 | Gilead Sciences, Inc. | 561 |
| #8 | Vertex Pharmaceuticals Incorporated | 334 |
| #9 | Merck Sharp & Dohme LLC | 1,248 |
| #10 | Janssen Pharmaceuticals, Inc. | 769 |
| #11 | CELGENE CORPORATION | 313 |
| #12 | Theravance Biopharma R&D IP, LLC | 239 |
| #13 | KING FAISAL UNIVERSITY | 803 |
| #14 | DAIICHI SANKYO COMPANY, LIMITED | 302 |
| #15 | Mitsubishi Gas Chemical Company, Inc. | 808 |
| #16 | GE HEALTHCARE LIMITED | 100 |
| #17 | Hoffmann-La Roche Inc. | 1,065 |
| #18 | AMGEN INC. | 875 |
| #19 | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH | 720 |
| #20 | Takeda Pharmaceutical Company Limited | 668 |
About This Class
CPC subclass C07B belongs to class C07.
8,058 patents were granted in this class between 2015 and 2025.
20 companies actively patent in this space.
Classification System
Cooperative Patent Classification (CPC) is a hierarchical patent classification system used by the USPTO and EPO.
Frequently Asked Questions
What is CPC class C07B?
How many patents have been filed in C07B?
Which company holds the most patents in C07B?
How is patent data for C07B collected?
What is the difference between CPC class and subclass?
Learn More
Explore the patent dataset
Read our methodology — how this data is sourced, computed, and verified.